Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942693 | 0.88 | LDHA (0.54) | LDHAL3MBTL1MMP13 | |
| SCHEMBL3776724 | 0.88 | LDHA (0.54) | LDHAL3MBTL1MMP13 | |
| SCHEMBL3638571 | 0.87 | LDHA (0.46) | LDHAADORA1L3MBTL1MMP13HTT | |
| SCHEMBL6318226 | 0.85 | REN (0.45) | L3MBTL1MMP13EPHX1AAK1ALDH1A1 | |
| SCHEMBL11358027 | 0.85 | REN (0.45) | L3MBTL1MMP13EPHX1AAK1ALDH1A1 | |
| SCHEMBL13010331 | 0.82 | LDHA (0.46) | LDHACYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL24443461 | 0.81 | MAPT (0.49) | LDHACYP2D6L3MBTL1MMP13POLB | |
| SCHEMBL31407616 | 0.80 | LDHA (0.46) | LDHAL3MBTL1MMP13F2RL1ALDH1A1 | |
| SCHEMBL17038560 | 0.79 | SLC6A4 (0.50) | LDHACYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL19200684 | 0.79 | REN (0.46) | LDHAMMP13AAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | LDHA 843/4885CYP1A2 2277/4885CYP2D6 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.